Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will GDUFA III Curtail Priority Assessments?

Executive Summary

US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.

You may also be interested in...



FDA And Industry Set Out GDUFA III Priorities

Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.

GDUFA III: First-Cycle Approval, Priority Assessment Improvements Are Early Priorities

Both issues have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.

GDUFA III: How Much Of A Fee Increase Can Industry Stomach?

Amid questions about generic industry market dynamics, the user fee renewal could focus on limiting increases in US FDA collections.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel